Suenaga, Ryo
Konagaya, Shuhei
Yamaura, Junji
Ito, Ryo
Tanaka, Satoshi
Ishizaki, Yoichi
Toyoda, Taro
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP21be0404008, JP21be0404008, JP21be0404008)
iPS Cell Research Fund
Article History
Received: 24 December 2021
Accepted: 17 March 2022
First Online: 25 March 2022
Competing interests
: This study was performed as a collaborative study between Kyoto University, Takeda Pharmaceutical Company, and Toyo Seikan Group Holdings. T.T. is a scientific advisor of Orizuru Therapeutics. The remaining authors declare no competing interests.